Advertisement

TheBodyPRO.com Covers CROI 2017

News

No Evidence of Accelerated Brain Aging in HIV-Positive People on Effective ART

February 17, 2017

A European study reported no evidence of accelerating brain aging in HIV-positive people in ART, based on highly sensitive brain imaging scans and cognitive testing over two years.

Although some differences were reported at baseline for the HIV positive group, the impact of ART in preventing further differences was significant in every domain.

The study was run in Amsterdam and London and is notable for including closely matched HIV-negative control groups. Results were presented at CROI 2017 in a in a late-breaker poster by James Cole from Imperial College London on behalf of the COBRA collaboration.1

Advertisement
The results are also important because people were following over time and the rates of change related to normal aging was able to be compared between HIV-positive and HIV-negative people with similar background risks. Neurocognitive changes are one of the leading concerns held by HIV-positive people, especially in relation to aging.

In this study, 134 HIV-positive people on ART with undetectable viral load for at least 12 months and a control group of 79 HIV-negative people were enrolled at the Amsterdam Medical Centre and Imperial College London. Retainment in the study was good with follow-up results available for 120/134 HIV-positive and 76/79 HIV-negative participants (at a median of just under two years (1.9 years).

Mean age at baseline was 57 years (SD +/- 7). In the HIV-positive group, the mean CD4 count was strong 646 cells/mm3 (+/- 213) and nadir CD4 showed historical HIV damage 185 (+/- 144) cells/mm3, reflecting a common history shared by many older HIV-positive people. Unfortunately, this was a largely male study, with only nine HIV-positive women and six HIV-negative women.

Neuroimaging was conducted using magnetic resonance imaging (MRI) for multiple regions at baseline and after two years, with changes adjusted for age, time between scans, intracranial volume and the type of scanner. Similar adjusted analysis were produced for neuropsychological assessments.

The main results showed that there were some differences between the two groups at baseline, with the HIV-positive group having slightly smaller grey matter volume (0.65 vs 0.68 L, p=0.02), abnormal white matter microstructure (p<0.01) and poorer cognitive function (in 4/7 functions: attention, processing speed, motor function and global cognitive performance, all p <0.01), compared to the HIV-negative group.

Mean changes between baseline and follow-up found no significant differences in any of the 14 scanning regions, including rate of grey matter loss, or in the 7 neuropsychological functions, and no consistent pattern of change in the positive vs negative groups. Cognitive performance also didn't reduce over time and global cognition score increased in both groups (+0.79 vs +0.45 in HIV positive vs HIV negative, respectively) -- suggesting that there may have been a learning effective from the repeated tests.

The researchers concluded that their analysis found no evidence of accelerated brain aging in HIV-positive people on ART compared to matched HIV-negative controls.

An ongoing analysis is looking for risk factors that can explain the slightly lower baseline results, perhaps related to duration of infection, time before starting ART, nadir CD4 count and lifestyle factors. The results will be just as important as the current study.

Simon Collins is a member of the scientific advisory board for the COBRA collaboration.


Comment

These results are reassuring and support another benefit to universal ART that is now recommended in treatment guidelines.

Although the potential factors that might explain the differences between the two groups at baseline were not discussed in the study, the lack of a long-term impact on the rate of further change, even in people who have had low CD4 nadir counts is also encouraging.

It is clearly important for similar research to look at whether results are similar for women, as the low numbers in this study mean it is not powered to show any differences.


Reference

Cole JH et al for the COBRA collaboration. Longitudinal analysis shows no evidence for accelerated brain ageing in treated HIV. CROI 2017, 13-16 February 2017, Seattle. Late breaker poster abstract 352LB.
www.croiconference.org/sessions/longitudinal-analysis-shows-no-evidence-accelerated-brain-ageing-treated-hiv (abstract and poster)


Related Stories

NRTI GS-9131 Resurfaces at CROI 2017: In Vitro Sensitivity to Nuke-Resistant HIV
Dolutegravir Exposure Increases When Fixed-Dose Combination Tablets Are Crushed
Pharmacokinetics and Full Phase 2 Results for Bictegravir, a New Integrase Inhibitor



Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.